Phase II efficacy and safety of Taro pharmaceuticals' pro-drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid) in patients with myoclonus dystonia: an open label sequential dose escalation study

Trial Profile

Phase II efficacy and safety of Taro pharmaceuticals' pro-drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid) in patients with myoclonus dystonia: an open label sequential dose escalation study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2013

At a glance

  • Drugs T 2000 (Primary)
  • Indications Dystonia
  • Focus Therapeutic Use
  • Sponsors Taro Pharmaceuticals USA
  • Most Recent Events

    • 25 Oct 2011 Planned end date changed from 1 Sep 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
    • 25 Oct 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 Nov 2010 Planned End Date changed from 1 Mar 2011 to 1 Sep 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top